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Abstract Purpose: This study sought to determine the
maximum tolerated dose of flat-dosed vinorelbine in
combination with capecitabine in patients with meta-
static breast cancer. At the time of study initiation, it
was anticipated that vinorelbine would be developed as
an oral capsule. A flat dosing scheme of both drugs was
used to facilitate development of the oral regimen, and
because neither drug’s clearance is associated with body
surface area (BSA), pharmacokinetic and pharmacoge-
netic endpoints were explored. Experimental Design:
Capecitabine was administered orally at 3,000 mg/day
on days 1–14. The starting dose of vinorelbine was
20 mg intravenously on days 1 and 8 of a 21-day cycle.
The vinorelbine dose was escalated until dose limiting
toxicity (DLT). Vinorelbine pharmacokinetics were
measured after the first dose. Patients underwent geno-
type analysis for polymorphisms in the CYP3A5 gene,
and the erythromycin breath test (ERMBT), a pheno-
typic test of CYP3A enzyme activity. Results: Twenty
five eligible patients were enrolled. Hematologic DLT
was seen at the 50 and 45 mg vinorelbine doses; thus the
recommended dose is 40 mg on days 1 and 8. Response
rate was 30%, and disease stabilization rate was 64%
(all dose levels included). Vinorelbine clearance was not
associated with ERMBT, BSA, or age. CYP3A5 geno-
type in this small sample did not have an obvious
relationship to clearance or toxicity. Conclusions: A
non-BSA based dosing scheme of capecitabine and
vinorelbine is safe and efficacious. BSA did not affect
vinorelbine clearance. We recommend future studies
with capecitabine and/or vinorelbine to compare the
safety and efficacy of flat dosed versus BSA-dosed
treatment.
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Introduction
The primary goals of treatment of metastatic breast
cancer are: (1) to improve quality of life by palliation of
symptoms, and (2) to lengthen survival. These goals are
most readily met in patients with hormone-responsive
tumors by the use of low-toxicity endocrine therapies.
Unfortunately, approximately 30% of breast cancers are
hormone receptor negative, and eventually hormone-
responsive metastatic disease becomes refractory to
endocrine manipulations. In hormone-refractory pa-
tients, combination chemotherapy results in higher re-
sponse rates, longer times to progression [23], and in
some studies prolonged overall survival [18], when
compared to single agent therapy. Unfortunately, these
benefits are often countered by increased toxicity and
complexity of the regimen [16]. An effective combination
chemotherapy regimen that is both simple and has low
toxicity would be of value.
Vinorelbine has been examined in combination with
3–5 day infusions of fluorouracil in advanced breast
cancer [6–9]. This combination has been well tolerated,
with response rates from 47–62% (both first line and
previously treated patients) [6–9]. However, continuous
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infusions of 5-fluorouracil are inconvenient due to the
need for a portable infusion pump and permanent ve-
nous access devices. Daily oral administration of che-
motherapeutic agents is much more convenient for
patients. Capecitabine, a nucleoside prodrug of 5-fluo-
rouracil with excellent oral bioavailability, is active in
patients with previously treated [3] or untreated [19]
metastatic breast cancer. The tolerability of vinorelbine
and capecitabine as single agents, their non-overlapping
toxicity profiles, and the previously demonstrated effi-
cacy of vinorelbine combined with continuous infusion
of fluorouracil makes this an attractive drug combina-
tion to evaluate further in metastatic cancer. At the time
we initiated this study, it was anticipated that vinorel-
bine, which has an excellent bioavailability profile, was
going to be developed as an oral capsule as well.
Normalizing drug doses to body surface area (BSA) is
the traditional approach to oncology drug dosing, but in
many cases it is not scientifically supportable [2, 20, 22].
This dosing approach has been validated for drugs for-
mulated in vehicles that cause drug volume distribution
to be similar to total blood volume (such as paclitaxel
solubilized in polyoxyethylated castor oil)[24]. In these
cases, BSA is possibly acting as a surrogate for drug
volume of distribution (Vss), since Vss approximates
total blood volume, which approximates BSA [24, 29].
It has been demonstrated that capecitabine clearance
is unrelated to BSA [2, 4].Variability in capecitabine
pharmacokinetics is likely to be primarily due to vari-
ability in the activity of the enzymes involved in cape-
citabine metabolism, and not body size [21]. Likewise,
clearance of drugs primarily metabolized by the liver,
such as vinorelbine, is not correlated with BSA [22].
Plasma clearance of vinorelbine is high, approaching
hepatic blood flow in humans, and its volume of distri-
bution is large, indicating extensive extravascular dis-
tribution [26]. For these reasons, we hypothesized that
BSA-based dosing of capecitabine and vinorelbine was
unnecessary. Thus, with the goal of increasing safety and
convenience, this study utilized a flat dosing scheme of
both capecitabine and vinorelbine. The dose of vino-
relbine was escalated based on a pharmacodynamic
toxicity, myelosuppression.
The metabolism of vinorelbine has been shown to be
mediated by hepatic cytochrome P450 isoenzymes in the
CYP3A subfamily.[10] This subfamily plays a dominant
role in the metabolism of more drugs than does any
other biotransformation enzyme. However, CYP3A
expression varies due to environmental stimuli (such as
smoking, drug intake or diet), by disease state (such as
hepatic dysfunction), and by genetic mutations. Genetic
variations in the CYP3A4 gene have not been shown to
be related to differences in CYP3A-dependent drug
clearance. However, polymorphisms in CYP3A5 have
been shown to cause variation in metabolism of such
drugs as cyclosporine[17] and midazolam.[5] The mutant
allele, CYP3A5*3[8] is associated with low CYP3A5
protein and this allele frequency varies from 50% in
African Americans to 90% in Caucasians.[12]
As exploratory endpoints, CYP3A5 genotype analy-
sis and vinorelbine pharmacokinetics were performed,
and vinorelbine clearance was correlated with age, BSA,
and the erythromycin breath test (ERMBT). The ER-
MBT has previously been shown to predict steady state
trough blood levels of drugs which are CYP3A sub-
strates [11]. We hypothesized that homozygosity for
CYP3A5*3 and low ERMBT would be associated with
reduced clearance of vinorelbine.
Patients and methods
Entry criteria
Eligible patients had metastatic breast cancer, with
measurable or evaluable disease by RECIST criteria.
Karnofsky performance status was ‡70, and patients
had normal hematologic, renal, and hepatic function
defined as ANC>1500, platelet count>100 K, calcu-
lated creatinine clearance>60 ml/min, AST/ALTPa-
tients were excluded if they had previous treatment with
continuous infusion or daily oral administration of flu-
orouracil, capecitabine, or vinca alkaloids and if they
had baseline Grade 2 or greater peripheral neuropathy,
or if they were pregnant or nursing. Patients who re-
quired concurrent treatment within 7 days prior to ini-
tial vinorelbine with drugs known to induce or inhibit
CYP3A activity were also ineligible. Excluded drugs
included midazolam, anti-mycotic agents (ketoconazole
and related compounds), macrolide antibiotics (eryth-
romycin and related compounds), nifedipine, anti-sei-
zure drugs, H2 blockers, grapefruit juice, and
rifampin.All patients signed an informed consent
regarding the experimental nature of this therapy after
approval by the University of Michigan Institutional
Review Board and in accordance with an assurance filed
with and approved by the Department of Health and
Human Services.
Treatment plan
This study was a Phase I/II study of the combination of
oral capecitabine and weekly intravenous vinorelbine.
Eligible patients were identified from the patient popu-
lation of the University of Michigan Health System.
Both agents were given flat doses regardless of BSA.
All chemotherapy was delivered on a 21-day cycle.
Capecitabine was administered orally at 1,500 mg twice
daily (3000 mg/day) on days 1–14. The starting dose of
vinorelbine was 20 mg administered intravenously
weekly on days 1 and 8. The dose was escalated in 10 mg
increments until dose limiting toxicity (DLT), which was
defined as Grade 3 or 4 toxicities (non-hematologic), or
Grade 3 or 4 thrombocytopenia at any time during the
first cycle. Neutropenia was considered dose-limiting if it
reached Grade 3 or 4 on day 21 in the first cycle. Once
DLT was defined, an intermediate dose level (5 mg)
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was tested, and if more than one-sixth of the patients
had DLT, the next lower dose level was used. The rec-
ommended Phase II dose was the dose at which one of
six or fewer patients experienced DLT. Subsequently,
eight additional patients were treated at the Phase II
dose in order to increase the sample size for secondary
analyses.
Prior to study treatment, the ERMBT was adminis-
tered in the outpatient setting within 2 weeks of the first
dose of vinorelbine, performed as previously de-
scribed.[27] Patients had blood drawn for pharmacoki-
netic analysis after the first administration of
vinorelbine. Blood was collected before infusion,
immediately at the end of infusion, and at 20, 45, 75 min
after infusion, then at 2, 3, 4, 6, 8 12, 24, 36, 48, and
72 h. Blood samples were analyzed for vinorelbine with
a liquid chromatography with mass spectrometry
method as described previously.[25] Pharmacokinetic
parameters were calculated using standard non-com-
partmental methods.
CYP3A5 Genotype determination
DNA was extracted from whole blood using the Qiagen
DNeasy Tissue kit and the QIAamp DNA Blood
Midi kit (Qiagen Inc., Valencia, CA, USA), respectively,
according the manufacture’s instructions and the yield
was determined by spectrophotometry (Beckman DU
640; Beckman Coulter, Inc., Fullerton, CA, USA).
DNA samples were assayed for the common CYP3A5*3
genetic polymorphism using polymerase chain reaction–
restriction fragment length polymorphism (PCR-RFLP)
assay as described previously [9].
Results
Dose escalation and toxicity
A total of 25 eligible patients were enrolled; all were
Caucasian with 24 females and 1 male. Patient charac-
teristics are described in Table 1. The flat-dosed cape-
citabine was well tolerated, as there were no instances
of Grade 3 hand–foot syndrome or diarrhea. Three
patients had a dose reduction for Grade 2 capecitabine
toxicity, including hand–foot syndrome and diarrhea.
There was no apparent relationship between BSA and
necessity for dose reduction of capecitabine.
The vinorelbine dose was escalated as described in
Table 2. All 25 patients completed at least two cycles of
treatment, and no patient discontinued therapy due to
toxicity. Three patients were treated at the 20 , 30 , and
40 mg dose levels with no DLT. At both the 50 mg and
45 mg dose levels, there were two hematologic DLTs
(Table 2).
Efficacy
Twenty of 25 (80%) patients had disease that was
measurable by RECIST criteria. Overall, six of the pa-
tients with measurable disease responded [30, 95% CI
(11.9–54.3)], with one complete response. Nine of 25
patients progressed within the first 12 weeks of treat-
ment (36, 95% CI [18.0–57.5]), and the remaining 16
patients had stable disease or better for over 12 weeks,
with a clinical benefit rate of 64, 95% CI (42.5–82.0).
Pharmacokinetics
Pharmacokinetic analysis of vinorelbine was performed
on the last 13 patients enrolled in the study, including 5
patients treated at 45 mg/week, and 8 patients treated at
40 mg/week. The mean vinorelbine clearance of the
Table 2 Genotype, ERMBT, body surface area (BSA), and dose
limiting toxicity (DLT)





1 NA 3.01 1.69 20.0 none
2 *3/*3 1.44 1.75 20.0 none
3 wt/*3 2.71 1.62 20.0 none
4 *3/*3 2.83 1.90 30.0 none
5 wt/*3 2.89 1.73 30.0 none
6 *3/*3 3.74 1.65 30.0 none
7 wt/*3 3.09 1.59 40.0 none
8 wt/*3 1.58 2.40 40.0 none
9 *3/*3 3.48 1.99 40.0 none
10 *3/*3 3.81 1.75 50.0 Low ANC
11 *3/*3 4.19 2.03 50.0 none
12 *3/*3 1.77 1.78 50.0 Low ANC
13 *3/*3 3.05 1.72 45.0 none
14 wt/*3 3.32 1.74 45.0 none
15 *3/*3 2.35 1.69 45.0 none
16 *3/*3 2.06 1.70 45.0 Low ANC
17 *3/*3 2.07 1.78 45.0 Low ANC
18 *3/*3 2.75 1.56 40.0 none
19 *3/*3 3.03 1.72 40.0 none
20 *3/*3 1.90 2.29 40.0 none
21 *3/*3 2.87 1.60 40.0 none
22 *3/*3 0.86 2.12 40.0 none
23 *3/*3 3.15 1.67 40.0 none
24 *3/*3 1.62 1.77 40.0 none
25 *3/*3 2.57 1.60 40.0 none
Table 1 Patient characteristics
Number of eligible patients 25
Average patient age (years) 50 (29–69)
Number with measurable disease 20 (80%)




Prior anthracycline 23 (92%)





population was 57.7 l/h (SD 12.7 l/h), similar to that
reported in the literature (Table 3) [13, 15, 26]. Clear-
ance in l/hr was found to be unrelated to BSA, age, or
ERMBT (Fig. 1). Vinorelbine was found to have a large
volume of distribution at steady state (Vss) of 1,428 l
(SD 510 l), as previously reported. BSA showed no
relationship to Vss of vinorelbine (Fig. 2).
CYP3A5 genotype
All patients were genotyped for the common CYP3A5*3
polymorphism. None of the patients were homozygous
wild-type, while 20% (n = 5) were heterozygous
CYP3A5*1/*3 and 80% (n = 20) were homozygous
variant CYP3A5*3/*3. the results consistent with known
allelic frequencies [11]. Low ERMBT result did not
predict heterozygous CYP3A5 genotype (Fig. 2).
Discussion
Our data demonstrate the feasibility and safety of flat
dosing of capecitabine and vinorelbine in a typical
metastatic breast cancer population. For this combina-
tion therapy we recommend flat-dose capecitabine
1,500 mg twice daily plus vinorelbine 40 mg on day 1
and day 8 as being efficacious and tolerable. In com-
parison with other trials of this combination, the median
BSA of our patient population was 1.74 m2, and the
average per-meter-squared dose of capecitabine deliv-
ered was 1,724 mg/m2 on days 1–14 (range 1,250–
1887 mg/m2). The recommended dose of vinorelbine in
our study averages 23 mg/m2 on days 1 and 8, of a 21-
day cycle. Three Phase I studies of vinorelbine and
capecitabine combination therapy in metastatic breast
cancer have been published. Two of the studies ulti-
mately recommended doses of capecitabine of 2,000 mg/
m2/d and vinorelbine 25 mg/m2 on days 1 and 8 [14, 28];
the other study in elderly patients recommended cape-
citabine 1,250 mg/m2/d and vinorelbine 20 mg/m2 on
days 1 and 8.[6]
Our patient population primarily included patients
being treated first- or second-line with chemotherapy,
but all had received prior taxanes and most had also
received prior anthracyclines, either in the metastatic
or adjuvant setting. The historical data would suggest
a 20%–30% response rate from single agent capecit-
abine in this population [3, 19]. The observed 30%
response rate and 65% disease stabilization rate
compares favorably to the historical sample, despite
the escalating doses of vinorelbine received by the
patients, with minimal hematologic or non-hemato-
logic toxicity.
The a priori hypothesis was that there would be no
association between toxicity of the flat-dosed combina-
tion regimen with BSA, and this hypothesis is supported
by our data. We also found no association between BSA
and clearance of vinorelbine, as has been previously
shown with capecitabine [4]. This is not surprising, since
the impact of BSA on the variability in drug pharma-
cokinetics is more likely to be apparent for drugs where
the distribution is similar to total blood volume (and
thus to BSA).
Despite the fact the vinorelbine is largely metabolized
by P450 enzymes of the CYP3A subfamily[10], there was
also no association noted between the ERMBT, vino-
relbine clearance, or toxicity. This observation suggests
that the ERMBT would not be a useful test in tailoring
the dose of vinorelbine to an individual’s metabolic
phenotype, in contrast to our finding in a prior study of
the ERMBT and docetaxel [7].
Only five patients in our population were heterozy-
gous for the CYP3A5*3 allele while the remainder were
homozygous CYP3A5*3. The CYP3A5*3 allele codes
for an aberrantly spliced mRNA with a premature stop
codon, therefore, patients with two CYP3A5*3 alleles
exhibit a nearly complete lack of CYP3A5 protein
expression [11]. We hypothesized that increased vino-
relbine clearance and decreased toxicity would correlate
with homozygosity for the wild-type CY3A5 allele (*1)
and less so with CYP3A5*1/*3. Since our study had
n=0 homozygous wild-type CYP3A5*1 and only n=5
heterozygous CYP3A5*3 patients, the lack of any
genotype/phenotype association makes a false negative
result highly likely. A larger study is needed to confirm
these results.
Table 3 Vinorelbine
pharmacokinetics in the study
population
AUC (0-¥) systemic exposure;
CL mean plasma clearance;
Cmax maximum concentration;
Tmax time to maximum con-
centration; t 1/2 terminal phase
half-life; Vss volume of distri-

















45.0 900.0 936.1 48.1 860.6 0.25 19.1 876.0
45.0 649.1 693.4 64.9 1000.6 0.15 31.9 1487.5
45.0 604.0 643.8 69.9 1073.0 0.15 35.6 1628.5
45.0 853.8 878.4 51.2 1185.8 0.17 23.6 885.7
45.0 762.3 806.8 55.8 918.5 0.17 33.0 1219.8
40.0 941.9 975.9 41.0 1516.7 0.17 25.2 744.7
40.0 625.5 665.9 60.1 598.1 0.27 26.2 1873.8
40.0 599.0 641.8 62.3 633.7 0.17 31.3 1553.6
40.0 959.6 1002.0 39.9 965.3 0.18 25.3 850.2
40.0 770.2 850.3 47.0 294.0 0.25 26.6 1330.6
40.0 679.7 767.3 52.1 1410.9 0.18 53.9 1677.0
40.0 395.7 440.7 90.8 360.8 0.18 46.6 2777.6
40.0 559.5 602.8 66.4 670.5 0.18 31.8 1657.6
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In conclusion, this study demonstrates that a non-
BSA-based dosing scheme of capecitabine and vinorel-
bine is safe and efficacious. Based on these data, we
recommend future studies with capecitabine and/or
vinorelbine to compare the safety and efficacy of
flat-dosed versus BSA-dosed treatment. We cannot
determine from this Phase I study whether this combi-
nation therapy is more effective than single-agent
sequential vinorelbine or capecitabine, and a random-
ized Phase III study would have to be performed in
order to make this treatment a standard recommenda-
tion [1] If vinorelbine is ever developed as an oral for-
mulation, further study of this combination therapy is
clearly indicated.
Fig. 1 Lack of relationship of Erythromycin breath test (ERMBT) (a) age or (b) body surface area (c) to vinorelbine clearance
Fig. 2 Volume of distribution
of vinorelbine is unrelated to
body surface area (BSA)
133
Acknowlegements This research was supported (in part) by the
National Institutes of Health through the University of Michigan’s
Cancer Center Support Grant (5 P30 CA46592) and National
Institutes of General Medical Sciences grant GM61373 (UO1).
Additional support was provided by GlaxoSmithKline, the Fashion
Footwear Association of New York/QVC Presents Shoes on Sale ,
and the University of Michigan General Clinical Research Center
Grant M01 RR000042. We would like to acknowledge the contri-
bution of A. Benjamin Suttle, Ph.D., Clinical Pharmacology and
Discovery Medicine, GlaxoSmithKline, Research Triangle Park,
North Carolina, for the pharmacokinetic analysis. Special thanks to
Janet Tarolli for her assistance in preparing this manuscript.
References
1. Baker LH, Vaughn CB, Al-Sarraf M, Reed ML,Vaitkevicius
VK (1974) Evaluation of combination vs. sequential cytotoxic
chemotherapy in the treatment of advanced breast cancer.
Cancer 33:513–518
2. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens
JHM, Grochow LB,Sparreboom A (2002) Role of body surface
area in dosing of investigational anticancer agents in adults,
1991–2001. JNCI Cancer Spect 94:1883–1888
3. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel
C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999)
Multicenter phase II study of capecitabine in paclitaxel-
refractory metastatic breast cancer. Journal of Clinical Oncol-
ogy 17:485–493
4. Cassidy J, Twelves C, Cameron D, Steward W, O’Byrne K,
Jodrell DI, Baken L, Goggin T, Jones D, Roos B, Bush E,
Wedidekamm E,Reigner B (1999) Bioequivalence to two tablet
formulations of capecitabine and exploration of age, gender,
body surface area, and creatinine clearance as factors influ-
encing systemic exposure in cancer patients. Cancer Chemother
& Pharmacol 44:453–460
5. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz
E, Lim R, Lim HL, Ong AB,Lee HS (2002) Explaining inter-
individual variability of docetaxel pharmacokinetics and
pharmacodynamics in Asians through phenotyping and geno-
typing strategies. J Clin Oncol 20:3683–3690
6. Hess D, Thurlimann B, Pagani O, Aebi S, Rauch D, Ballabeni
P, Rufener B, Castiglione-Gertsch M, Goldhirsch A, Swiss
Group of Clinical Cancer Research (2004) Capecitabine and
vinorelbine in elderly patients (>or=65 years) with metastatic
breast cancer: a phase I trial (SAKK 25/99). Ann Oncol
15:1760–1765
7. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R,
Baker LH (2000) The effect of an individual’s cytochrome
CYP3A4 activity on docetaxel clearance. Clin Cancer Res
6:1255–1258
8. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K,
Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A,
Brockmoller J, Halpert JR, Zanger UM,Wojnowski L (2001)
The genetic determinants of the CYP3A5 polymorphism.
Pharmacogenetics 11:773–779
9. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T,
Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer
L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes
DF,Flockhart DA (2005) CYP2D6 genotype, antidepressant
use, and tamoxifen metabolism during adjuvant breast cancer
treatment. J Natl Cancer Inst 97:30–39
10. Kajita J, Kuwabara T, Kobayashi H,Kobayashi S (2000)
CYP3A4 is mainly responsibile for the metabolism of a new
vinca alkaloid, vinorelbine, in human liver microsomes. Drug
Metab Dispos 28:1121–1127
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J,
Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling
M, Brimer C, Yasuda K, Venkataramanan R, Strom S,
Thummel K, Boguski MS,Schuetz E (2001) Sequence diversity
in CYP3A promoters and characterization of the genetic basis
of polymorphic CYP3A5 expression. Nat Genet 27:383–391
12. Lamba JK, Lin YS, Schuetz EG,Thummel KE (2002) Genetic
contribution to variable human CYP3A-mediated metabolism.
Adv Drug Deliv Rev 54:1271–1294
13. Leveque D,Jehl F (1996) Clinical pharmacokinetics of vino-
relbine. Clin Pharmacokinet 31:184–197
14. Lorusso V, Crucitta E, Silvestris N, Guida M, Misino A, La-
torre A,De Lena M (2003) A phase I study of capecitabine in
combination with vinorelbine in advanced breast cancer. Clin
Breast Cancer 4:138–141
15. Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F,Nicot
G (1992) Pharmacokinetics of vinorelbine in man. Eur J Clin
Pharmacol 42:545–547
16. Miles D, von Minckwitz G,Seidman AD (2002) Combination
versus sequential single-agent therapy in metastatic breast
cancer. Oncologist 7(suppl 6):13–19
17. Min DI, Ellingrod VL, Marsh S,McLeod H (2004) CYP3A5
polymorphism and the ethnic differences in cyclosporine phar-
macokinetics in healthy subjects. Ther Drug Monit 26:524–528
18. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub
JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L,
Twelves C, Van Hazel G, Verma S,Leonard R (2002)
Superior survival with capecitabine plus docetaxel combina-
tion therapy in anthracycline-pretreated patients with ad-
vanced breast cancer: phase III trial results. J Clin Oncol
20:2812–2823
19. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D,
Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU,Laws
S (2001) Randomized, open-label, phase II trial of oral cape-
citabine (Xeloda) vs. a reference arm of intravenous CMF
(cyclophosphamide, methotrexate and 5-fluorouracil) as first-
line therapy for advanced/metastatic breast cancer. Ann Oncol
12:1247–1254
20. Ratain MJ (1998) Body-surface area as a basis for dosing of
anticancer agents: science, myth, or habit? J Clin Oncol
16:2297–2298
21. Reigner B, Blesch K,Weidekamm E (2001) Clinical pharma-
cokinetics of capecitabine. Clin Pharmacokinet 40:85–104
22. Sawyer M,Ratain MJ (2001) Body surface area as a determi-
nant of pharmacokinetics and drug dosing. Invest New Drugs
19:171–177
23. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S,
Rowinsky EK,Wood WC (2003) Phase III trial of doxorubicin,
paclitaxel, and the combination of doxorubicin and paclitaxel
as front-line chemotherapy for metastatic breast cancer: an
intergroup trial (E1193). J Clin Oncol 21:588–592
24. Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G,
Nooter K,Verweij J (2003) Randomized cross-over evaluation
of body-surface area-based dosing versus flat-fixed dosing of
paclitaxel.[see comment]. J Clin Oncol 21:197–202
Fig. 3 ERMBT results in the heterozygous and homozygous
mutant genotypes seen
134
25. VanHeugen J, DeGraeve J, Zorza G, Puozzo C (2001) New
sensitive liquid chromatography method coupled with tandem
mass spectrometric detection for the clinical analysis of vino-
relbine and its metabolites in blood, plasma, urine and faeces. J
Chromatogr A 926:11–20
26. Wargin WA,Lucas VS (1994) The clinical pharmacokinetics of
vinorelbine (Navelbine). Semin in Oncol 21:21–27
27. Watkins PB (1994) Noninvasive tests of CYP3A enzymes.
Pharmacogenetics 4:171–184
28. Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher
R, Loibl S, Harstrick A, Kaufmann M, Seeber S,Vanhoefer U
(2005) Phase I/II study of capecitabine and vinorelbine in
pretreated patients with metastatic breast cancer. Ann Oncol
16:64–69
29. Wolner E, Domanig E Jr, Elkadi A, Helmer F, Romer P (1968)
On a simple relation between blood volume and body surface
area. Z Kreislaufforsch 57(1):79–84
135
